Protein tyrosine kinase (PTK) is one of the major signaling enzymes in the process of cell
signal transduction, which catalyzes the transfer of ATP-γ-phosphate to the tyrosine residues …

The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …

Drug resistance caused by epidermal growth factor receptor (EGFR) mutation has largely
limited the clinical use of EGFR tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of …

Abstract Development of biological targeted therapies and immune checkpoint inhibitors has
redefined the treatment for many cancers; however, the increasing use of new protocols has …

Cancer is a complex disease emerging from uncontrolled cell proliferation and division due
to various genetic and environmental factors. Even though standard procedures are applied …

This review examines the vast catalytic and therapeutic potential offered by type I (ie oxygen-
insensitive) nitroreductase enzymes in partnership with nitroaromatic prodrugs, with …

Five-year survival for pancreatic ductal adenocarcinoma (PDAC) patients remains below 7%
due to the lack of effective treatments. Here, we report that combined ablation of EGFR and c …

Cardiotoxic effects of chemotherapy and targeted drugs are ubiquitous and challenging in
the field of oncology therapeutics. The broad spectrum of toxicities ranging from ischemic …